Vineeta Kumar
Nephrology · Birmingham, ALNPI 1033146790
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,002 of the $58,830 with a category attached, or 74.8%. AstraZeneca accounts for 63.8% of it on its own, with 7 other manufacturers making up the rest. Among nephrology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $2028.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Novartis$10K
- Apellis Pharmaceuticals, Inc.$9K
- Fresenius USA Marketing, Inc.$1K
- Sanofi-aventis U.S. LLC$162
- Novo Nordisk$125
- plus $159 from 2 others
What the payments were for
- Consulting fees$44,00275%
- Speaking & faculty fees$1,3002%
- Travel & lodging$12,43521%
- Food & beverage$9312%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $37,540 |
| Novartis | 8 | $10,284 |
| Apellis Pharmaceuticals, Inc. | 2 | $9,260 |
| Fresenius USA Marketing, Inc. | 1 | $1,300 |
| Sanofi-aventis U.S. LLC | 2 | $162 |
| Novo Nordisk | 1 | $125 |
| GSK | 1 | $85 |
| United Therapeutics Corporation | 2 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,830 in reported general payments places this provider in the 90th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 24 | $13,050 |
| EliquisApixaban | 11 | $8,658 |
| Tacrolimus | 18 | $1,274 |
| Prednisone | 100 | $1,106 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 147 | $874 |
| Azithromycin | 11 | $800 |
| Calcitriol | 31 | $666 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $584 |
| Tamsulosin Hcl | 25 | $578 |
| Nifedipine ErNifedipine | 30 | $546 |
| Carvedilol | 76 | $531 |
| Pantoprazole Sodium | 67 | $504 |
| Losartan Potassium | 64 | $431 |
| Atorvastatin Calcium | 34 | $364 |
| Lisinopril | 19 | $234 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Ashita TolwaniBirmingham$56K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
- Timmy LeeBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.